无创性滤泡性甲状腺肿瘤伴乳头状核特征(NIFTP)全球发病率:一项评估重新分类影响的荟萃分析
该荟萃分析纳入50项回顾性研究,共100,780例甲状腺乳头状癌(PTC)和3,990例NIFTP,来自全球92家机构。NIFTP在PTC中的总体发病率为6.0%(95%CI 4.4-8.2),亚洲(2.1%)显著低于北美(9.3%)和欧洲(9.6%)。重新分类可能每年使全球约30,881例患者免于甲状腺癌诊断。
要点
- NIFTP在PTC中的全球总体发病率为6.0%(95%CI 4.4-8.2)。
- 亚洲NIFTP发病率(2.1%)显著低于北美(9.3%)和欧洲(9.6%)。
- 重新分类每年可能使全球约30,881例患者免于甲状腺癌诊断。
核心结论
- 全球NIFTP发病率远低于最初估计,且亚洲显著低于北美和欧洲。
- NIFTP的引入每年可能使全球超过30,000例患者免于甲状腺癌诊断的临床和心理后果。
研究设计与样本
- 荟萃分析,检索PubMed和Web of Science 2016年1月1日至2021年1月30日共五年文献。
- 从505篇出版物中纳入50项回顾性研究,共100,780例PTC和3,990例NIFTP,来自全球92家机构。
- 采用随机效应模型合并比例及95%置信区间,用I2统计量评估异质性,Egger回归检验和漏斗图评估发表偏倚。
主要发现
- NIFTP在PTC中的总体发病率为6.0%(95%CI 4.4-8.2),研究间异质性高(I2=98.6%)。
- 北美和欧洲NIFTP发病率相似(9.3% vs. 9.6%),亚洲总体发病率显著更低(2.1%)。
- 2017年后发表的非亚洲研究中NIFTP报告发病率显著下降(p=0.002)。
- 将数据应用于全球甲状腺癌统计,该重新分类每年将影响约30,881例患者,亚洲影响低于北美和欧洲。
关键数值与推荐
- NIFTP发病率计算为NIFTP数量除以PTC数量。
- p值<0.05认为显著。
临床怎么用
- 临床应认识到NIFTP发病率存在地理差异,亚洲患者中NIFTP比例较低。
- NIFTP诊断可避免部分患者承受甲状腺癌诊断的临床和心理负担。
局限性
- 纳入研究均为回顾性研究。
- 研究间异质性高(I2=98.6%)。
- NIFTP发病率受研究性质、样本收集数据库类型和诊断标准影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) reclassification has significantly influenced the field of thyroidology. However, the extent of this impact depends upon the incidence of NIFTP in a given population. In this meta-analysis, we aimed to obtain robust information about the actual incidence of NIFTP worldwide by reviewing the published data. Methods: Comprehensive literature search was performed using electronic databases of PubMed and Web of Science over a five-year period (January 1, 2016, to January 30, 2021). The incidence of NIFTP was calculated by dividing the number of NIFTPs by the number of papillary thyroid carcinomas (PTCs). Meta-analysis of proportion and their 95% confidence interval [CI] were pooled using the random-effect model. Heterogeneity across the included studies was assessed using I2 statistics. Egger's regression test and funnel plot of estimates were used to evaluate the publication bias. p-Value <0.05 was considered significant. Results: From 505 publications, we included 50 studies, all retrospective, with 100,780 PTCs and 3990 NIFTP from 92 institutions worldwide. The overall incidence of NIFTP was 6.0% [CI 4.4-8.2] among PTCs or thyroid malignancies with a high level of heterogeneity among the included studies (I2 = 98.6%). NIFTP incidence was largely similar in North America and Europe (9.3% vs. 9.6%), with a significantly lower overall rate in Asia (2.1%). There was a significant decline in the reported incidence of NIFTP in non-Asian studies published after 2017 (p = 0.002). On applying our data on global thyroid cancer statistics, this reclassification would affect ∼30,881 patients annually, with a lower impact in Asia compared with North America and Europe. Conclusions: This comprehensive meta-analysis confirms that the worldwide NIFTP incidence is much lower than estimated initially. The NIFTP rates are significantly lower in Asian compared with North American and European countries. Apart from geography, NIFTP rates are significantly influenced by the nature of study, type of database used for sample collection, and the diagnostic criteria used. Introduction of NIFTP may potentially spare over 30,000 patients worldwide annually from clinical and psychological consequences of a thyroid cancer diagnosis.
引用
- Rana C, Vuong HG, Nguyen TQ, et al. The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification. Thyroid. 2021. PMID: 34060946. doi:10.1089/thy.2021.0158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。